BSIM²

Our mission is to improve the lives of patients affected by transthyretin amyloidoses through innovative therapeutic approaches. We are developing next generation transthyretin stabilizers tailored to treat TTR-FAP co-morbidities, employing artificial intelligence and biomolecular simulation techniques.